An observational study in Heart Failure, sponsored by University of Leeds. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by University of Leeds · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Heart Failure by University of Leeds — 4 open to participants now, 5 under way, none of them phase 3. Heart Failure · University of Leeds.
Among the 15 studies in Heart Failure by University of Leeds, this one is the only one that started in 2026, is one of 5 observational ones, and was the 14th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →4 of the 15 studies in Heart Failure by University of Leeds are open now, in 1 country. Recruiting first, the newest first:
University of Leeds · Sites in United Kingdom
Ages 18+ · Healthy volunteers
University of Leeds · Sites in United Kingdom
Ages 18+ · Healthy volunteers
University of Leeds · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 475 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 87 across the 10 interventional studies, 475 across the 5 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Leeds is the lead sponsor of 206 studies on the registry; 25 are open to participants now.
1 of the studies in Heart Failure by University of Leeds that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07367841University of LeedsFIND HF Risk-guided Screening for Heart Failure - Pilot Study | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Heart Failure by University of Leeds, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the FIND HF algorithm detection rates of heart failure during testing are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk in a population identified as at risk of undiagnosed heart failure. The main questions it aims to answer are:
Participants will attend one visit at a local clinic where they will undergo an NT proBNP blood test which indicates heart failure and an echocardiogram to evaluate the heart's chambers, valves and overall function to help diagnose various heart conditions.
Background Heart failure (HF) affects around 1-2% of adults globally and is a leading cause of unplanned hospital admissions, especially among older people. In the UK alone, over one million people have HF, with about 200,000 new cases each year. This increase is mainly due to an aging population and better survival rates following heart attacks.
From the perspective of treatment, there are three main categories of HF:
In the UK, nurse-led teams in the community are capable of initiating and adjusting HF treatments. However, diagnosing HF early, before severe symptoms appear, remains challenging. Current guidelines recommend specific tests for diagnosis, but many (8 out of 10) diagnoses are still made in hospitals, often late.
The NHS aims to improve early diagnosis in primary care to reduce hospital admissions and improve patients' quality of life.
Funded by the British Heart Foundation (BHF) the investigators have developed an AI algorithm, FIND-HF, to identify people at risk of undiagnosed HF using data from routinely collected electronic health records.
Aims of the project The research project aims to determine the effectiveness of the FIND-HF AI algorithm in identifying HF at different risk levels and to understand the potential benefits of early detection and treatment.
The investigators will quantify the burden of symptoms, natriuretic peptide levels, and diagnostic yield of asymptomatic left ventricular systolic dysfunction, HFrEF, HFmrEF, and HFpEF at different FIND-HF AI risk scores. Using this information, the investigators will establish the risk score threshold that would be used for a future randomised clinical trial (RCT) of early detection of HF.
In addition, amongst patients newly diagnosed with HF during the study, the investigators seek to quantify the pharmacological treatment opportunities to inform the potential effect size, and thus sample size, of a future RCT of early detection and treatment of HF to reduce heart failure hospitalisation and cardiovascular death.
Identification of participants and recruitment Participants will be identified through by having their HF risk estimated their primary care electronic health records.
Individuals will be divided into two categories based on the predicted HF risk with recruitment 1:2 guided by risk strata, with 151 participants in the top 10 percentiles of risk, and 302 participants from the bottom 90 percentiles. This approach aims to enrich the cohort with higher risk patients while also including lower risk patients to determine whether there is an increase in the yield of new HF diagnosis from across the range of FIND-HF AI risk estimates.
Study invitations will be sent to eligible participants in each risk category in batches until the target sample size is reached. The invitation process will consist of a text message followed by an information pack in the post including a participant information sheet, consent form, contact information form and freepost return envelope. Participants will return the consent form and contact information to the research team who will then contact them to make an appointment for the study visit. The study visit will take place at the participant's GP surgery or a community-based health hub.
All participants will be required to provide written informed consent. Study visit
Consenting participants will attend one study visit. During the visit, a British Society of Echocardiography (BSE)-accredited clinical member of the research team will carry out the following tests/investigations:
New cases of HF will be reported to the participant and their GP. Their GP will have responsibility to refer the participant as per local protocol.
Follow up Participants will be followed up remotely through their primary care EHRs at 6 months, and 1-, 5- and 10-years from their study visit by a member of the research team. Follow-up will include assessment of HF therapy and HF events. Consent will be sought for linkage to secondary care records, death certificate data and national registries.
Expected value of results The NHS Major Conditions Strategy stresses the need for evolving care models to better serve the public, with a focus on early diagnosis of cardiovascular disease using AI and digital technology. This proof-of-concept study will inform the design of a trial to test AI risk stratification and community-based pathways for early diagnosis and treatment of heart failure (HF), aiming to reduce HF events and cardiovascular death. If successful, the AI model (FIND-HF) could be implemented across UK primary care for a community-based early HF diagnostic pathway in the NHS.
Patients identified at risk of developing Heart Failure by the FIND HF algorithm and are aged 40 and over, living in the Yorkshire area.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Registered with a doctor practice that uses electronic health system to record patient medical notes Age at enrolment greater or equal to 40 Identified as at risk of developing Heart Failure
Exclusion Criteria:
Registered with a doctor practice that is participating in research studies relating to heart failure screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will attend one visit with a Cardiology specialist Clinical research fellow who will carry out tests to detect Heart Failure
Diagnostic Test: FIND HF algorithm
Algorithm developed by the research team to identify patients at risk of heart failure that is currently undetected.
To determine whether detection rates of a composite of asymptomatic LVSD, HFrEF, HFmREF, or HFpEF during diagnostics are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk
Odds ratio of asymptomatic LVSD, HFrEF, HFmREF, or HFpEF detection rates from intervention in people identified as high HF risk compared with people identified as low HF risk
Time frame: Through study completion, an average of 12 months from date of enrolment
To determine if components of composite outcome during diagnostics are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk
Odds ratio for each component of the composite in in people identified as high HF risk compared with people identified as low HF risk
Time frame: Through study completion, an average of 12 months from date of enrolment
Plan to share: No — Planning to commercialise algorithm
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 10 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Sep 2026, on Oct 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.